As previously reported, B. Riley FBR analyst David Buck upgraded Amag Pharmaceuticals to Buy from Neutral after the company agreed to sell Cord Blood Registry to private equity firm GI Partners for $530M in cash. The divestiture should allow the company to retire senior debt and become net debt free, which would eliminate his concern about Amag being highly-leveraged, Buck tells investors. Despite the "negative optics" of selling for below the $700M it paid to buy CBR, Buck sees the choice to divest as strategically sound, the analyst added. He raised his price target on Amag shares to $30 from $23, citing switching to Makena auto-injector, growth for Intrarosa and an early 2019 FDA approval for bremalanotide as key catalysts.